GU Cancers 2024 | Sequencing ADCs and finding novel biomarkers for urothelial carcinoma

Rohit Jain, MD, MPH, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, comments on the novel developments in the field of antibody-drug conjugates (ADCs) for urothelial carcinoma. Enfortumab vedotin plus pembrolizumab has been proven to be efficacious in the first-line setting for locally advanced metastatic urothelial carcinoma, and chemotherapy or erdafitinib can be utilized afterwards. Sacituzumab govitecan is recommended after chemotherapy due to lower responses. Dr Jain additionally highlights the UNITE study, which will retrospectively elucidate novel biomarkers. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.